Affimed Appoints New CEO, Shares Fall on Leadership Change

Zacks09-04

Affimed N.V. AFMD announced that it has appointed Shawn M. Leland as the company’s new chief executive officer (CEO). Shares of the company were down 6.6% on Sep 3 following the announcement of the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2465581054?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/UtFJmA2Sogt3ia9UtBrVtA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/90c6165961c32b679207868449ac44ae","is_english":true,"pubTime":"2024-09-04 23:26","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2465581054","market":"us","top_or_hot":-1,"title":"Affimed Appoints New CEO, Shares Fall on Leadership Change","media":"Zacks","content":"<div>\n<p>Affimed N.V. AFMD announced that it has appointed Shawn M. Leland as the company’s new chief executive officer (CEO). Shares of the company were down 6.6% on Sep 3 following the announcement of the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/affimed-appoints-ceo-shares-fall-152600736.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Affimed Appoints New CEO, Shares Fall on Leadership Change</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAffimed Appoints New CEO, Shares Fall on Leadership Change\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-04 23:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/affimed-appoints-ceo-shares-fall-152600736.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Affimed N.V. AFMD announced that it has appointed Shawn M. Leland as the company’s new chief executive officer (CEO). Shares of the company were down 6.6% on Sep 3 following the announcement of the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/affimed-appoints-ceo-shares-fall-152600736.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03165","symbol_name":"华夏欧优股对冲","start_time":0,"source_url":"https://finance.yahoo.com/news/affimed-appoints-ceo-shares-fall-152600736.html","article_id":"2465581054","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/UtFJmA2Sogt3ia9UtBrVtA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/90c6165961c32b679207868449ac44ae"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2465581054","pubTimestamp":1725463560,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Affimed N.V. AFMD announced that it has appointed Shawn M. Leland as the company’s new chief executive officer . Shares of the company were down 6.6% on Sep 3 following the announcement of the news.Leland will replace Andreas Harstrick who has been the acting CEO of Affimed since January 2024. The latter will continue in his role as the chief medical officer.Leland most recently served as the interim CEO and board director of ForeBio. Previously, he held various senior leadership positions at Verastem Oncology and Argos Therapeutics.He also founded Elevation Oncology and served as its CEO until January 2023.Year to date, shares of Affimed have plunged 36.8% against the industry’s 0.6% increase.In the past 60 days, estimates for Illumina’s 2024 earnings per share have moved up from $1.18 to $3.62. Earnings per share estimates for 2025 have improved from $2.93 to $4.50. Year to date, shares of ILMN have lost 6.4%.In the past 60 days, estimates for Fulcrum Therapeutics’ 2024 loss per shar","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"03165":"华夏欧优股对冲","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","FULC":"Fulcrum Therapeutics","BK4121":"生命科学工具和服务","BK4585":"ETF&股票定投概念","CEO":"中海油","ILMN":"Illumina","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4588":"碎股","AFMD":"Affimed NV","BK4007":"制药","RHHBY":"罗氏控股"},"translate_title":"Affimed任命新首席执行官，股价因领导层变动而下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CEO":1,"FULC":1,"ILMN":1,"RHHBY":1,"AFMD":0.9,"03165":0.6},"content_text":"Affimed N.V. AFMD announced that it has appointed Shawn M. Leland as the company’s new chief executive officer (CEO). Shares of the company were down 6.6% on Sep 3 following the announcement of the news.\nLeland will replace Andreas Harstrick who has been the acting CEO of Affimed since January 2024. The latter will continue in his role as the chief medical officer.\nLeland most recently served as the interim CEO and board director of ForeBio. Previously, he held various senior leadership positions at Verastem Oncology and Argos Therapeutics.\nHe also founded Elevation Oncology and served as its CEO until January 2023.\nAFMD Stock Underperforming Industry\nYear to date, shares of Affimed have plunged 36.8% against the industry’s 0.6% increase.\nImage Source: Zacks Investment Research\nThe company’s clinical-stage pipeline comprises three investigational candidates, AFM24, acimtamig (AFM13) and AFM28, which are currently being developed either as a monotherapy or in combination therapies with other agents for several oncology indications.\nAffimed currently generates revenues related to a platform license provided to Genentech, a subsidiary of Swiss drug giant Roche RHHBY.\nAFMD’s Pipeline Development\nThe phase I/IIa AFM24-102 study is evaluating AFM24 in combination with Roche’s oncology drug, Tecentriq (atezolizumab), for the treatment of refractory patients with non-small cell lung cancer (NSCLC).\nRoche’s Tecentriq is currently approved in the United States, EU and several other countries to treat some of the most aggressive and difficult-to-treat forms of cancer, including advanced lung cancer, urothelial cancer and breast cancer.\nThe LuminICE-203 study is evaluating acimtamig in combination with AlloNK cells in patients with refractory Hodgkin's Lymphoma.\nAffimed is also evaluating AFM28 as a monotherapy in a phase I dose-escalation study for the treatment of refractory acute myeloid leukemia.\nIn the absence of a marketed product, the successful development of its pipeline candidates remains the key focus for this clinical-stage company.\nAlso, it remains to be seen how the new CEO conducts Affimed’s ongoing business operations along with its pipeline development activities.\nZacks Rank & Stocks to Consider\nAffimed currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks in the biotech sector are Illumina, Inc. ILMN and Fulcrum Therapeutics, Inc. FULC, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nIn the past 60 days, estimates for Illumina’s 2024 earnings per share have moved up from $1.18 to $3.62. Earnings per share estimates for 2025 have improved from $2.93 to $4.50. Year to date, shares of ILMN have lost 6.4%.\nILMN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 463.46%.\nIn the past 60 days, estimates for Fulcrum Therapeutics’ 2024 loss per share have narrowed from $1.24 to 48 cents. Loss per share estimates for 2025 have narrowed from $1.71 to $1.51. Year to date, shares of FULC have jumped 20%.\nFULC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 393.18%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nRoche Holding AG (RHHBY) : Free Stock Analysis Report\nIllumina, Inc. (ILMN) : Free Stock Analysis Report\nAffimed N.V. (AFMD) : Free Stock Analysis Report\nFulcrum Therapeutics, Inc. (FULC) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.27.0","shortVersion":"4.27.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2465581054"}